{"id":116,"date":"2025-12-23T23:31:53","date_gmt":"2025-12-23T23:31:53","guid":{"rendered":"https:\/\/peanutimmunotherapy.scot\/?p=116"},"modified":"2025-12-23T23:33:07","modified_gmt":"2025-12-23T23:33:07","slug":"vitesse-trial","status":"publish","type":"post","link":"https:\/\/peanutimmunotherapy.scot\/?p=116","title":{"rendered":"Vitesse trial"},"content":{"rendered":"\n<p>VITESSE trial of epicutaneous (patch, in other words) immunotherapy for peanut allergy <a href=\"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskin-peanut-patch-in-peanut-allergic-children-aged-4-7-years\/\" data-type=\"link\" data-id=\"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskin-peanut-patch-in-peanut-allergic-children-aged-4-7-years\/\">has reported successful results<\/a> &#8211; this is the largest food immunotherapy trial ever performed, across US, Canada, Europe and Australia. <\/p>\n\n\n\n<p>Results have not been formally presented or published yet.<\/p>\n\n\n\n<p>This is a commercial product, called Viaskin. 654 patients between the ages of 4 and 7 years were involved. <\/p>\n\n\n\n<p>At 1 year, 46.6% of children treated with the Viaskin peanut patch achieved the end goal of passing a 300mg challenge (1.5 peanuts) if low threshold at the start, or else 600mg challenge if high starting threshold (100mg or higher). This is a much lower success rate than found with oral peanut (Palforzia).<\/p>\n\n\n\n<p>Less adverse effects though &#8211; only 3.2% of patients discontinued treatment due to adverse events. There were no reports of treatment-related serious adverse events. Treatment-related anaphylaxis occurred in 0.5% of treated children (2), and both participants continued therapy. <\/p>\n\n\n\n<p>So this might be appealing to families who are worred about side effects of treatment or patients who have struggled with taking oral doses of peanut because of the taste.<\/p>\n\n\n\n<p>It would be nice to know the cost, what it&#8217;s like to wear the patch, whether there are restrictions on activities such as exercise, as there are with Palforzia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>VITESSE trial of epicutaneous (patch, in other words) immunotherapy for peanut allergy has reported successful results &#8211; this is the largest food immunotherapy trial ever performed, across US, Canada, Europe and Australia. Results have not been formally presented or published yet. This is a commercial product, called Viaskin. 654 patients between the ages of 4 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,6],"tags":[],"class_list":["post-116","post","type-post","status-publish","format-standard","hentry","category-research","category-treatment"],"_links":{"self":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/posts\/116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=116"}],"version-history":[{"count":2,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/posts\/116\/revisions"}],"predecessor-version":[{"id":118,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=\/wp\/v2\/posts\/116\/revisions\/118"}],"wp:attachment":[{"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peanutimmunotherapy.scot\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}